Biosimilars: Reimbursement Issues in Your Oncology Practice

被引：5

作者：

Conti, Rena M. ^{[1
]}

机构：

[1] Univ Chicago, 5841 S Maryland Ave,WP C432, Chicago, IL 60637 USA

来源：

JOURNAL OF ONCOLOGY PRACTICE | 2017年 / 13卷 / 09期

关键词：

CANCER;

D O I：

10.1200/JOP.2017.025783

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：12S / +

页数：4

共 12 条

[1] Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation [J].

Berndt, Ernst ;

Aitken, Murray .

INTERNATIONAL JOURNAL OF THE ECONOMICS OF BUSINESS, 2011, 18 (02) :177-201

[2]

Cauchi Richard., 2017, STATE LAWS LEGISLATI

[3]

Conti R., WHY ARE CANC DRUGS C

[4]

Conti RM, 2012, AM J MANAG CARE, V18, pE173

[5] Mitigating Financial Toxicity Among US Patients With Cancer [J].

de Souza, Jonas A. ;

Conti, Rena M. .

JAMA ONCOLOGY, 2017, 3 (06) :765-766

[6] Association of Prescription Drug Price Rebates inMedicare Part D With Patient Out-of-Pocket and Federal Spending [J].

Dusetzina, Stacie B. ;

Conti, Rena M. ;

Yu, Nancy L. ;

Bach, Peter B. .

JAMA INTERNAL MEDICINE, 2017, 177 (08) :1185-1188

[7] Obstacles to the Adoption of Biosimilars for Chronic Diseases [J].

Hakim, Aaron ;

Ross, Joseph S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (21) :2163-2164

[8]

Meek T, NORDIC COUNTRIES NEA

[9]

Quintiles IMS Institute, MED US SPEND US REV

[10] Addressing the Financial Burden of Cancer Treatment From Copay to Can't Pay [J].

Shankaran, Veena ;

Ramsey, Scott .

JAMA ONCOLOGY, 2015, 1 (03) :273-274

← 1 2 →